Plasma β-Amyloid in Mild Behavioural Impairment – Neuropsychiatric Symptoms on the Alzheimer’s Continuum

Journal of Geriatric Psychiatry and Neurology, Journal Year: 2021, Volume and Issue: 35(3), P. 434 - 441

Published: May 26, 2021

Introduction: Simple markers are required to recognize older adults at higher risk for neurodegenerative disease. Mild behavioural impairment (MBI) and plasma β-amyloid (Aβ) have been independently implicated in the development of incident cognitive decline dementia. Here we studied associations between MBI Aβ 42 /Aβ 40 . Methods: Participants with normal cognition (n = 86) or mild 53) were selected from Alzheimer’s Disease Neuroimaging Initiative. scores derived Neuropsychiatric Inventory items. Plasma ratios assayed using mass spectrometry. Linear regressions fitted assess association total score as well domain Results: Lower was associated ( p 0.04) greater affective dysregulation 0.04), but not impaired drive/motivation 0.095) impulse dyscontrol 0.29) domains. Conclusion: In persons impairment, low Incorporating into case detection may help capture preclinical prodromal

Language: Английский

---

Alzheimer’s disease – the journey of a healthy brain into organ failure

Molecular Neurodegeneration, Journal Year: 2022, Volume and Issue: 17(1)

Published: March 5, 2022

As the most common dementia, Alzheimer's disease (AD) exacts an immense personal, societal, and economic toll. AD was first described at neuropathological level in early 1900s. Today, we have mechanistic insight into select aspects of pathogenesis ability to clinically detect diagnose underlying pathologies living patients. These insights demonstrate that is a complex, insidious, degenerative proteinopathy triggered by Aβ aggregate formation. Over time pathology drives neurofibrillary tangle (NFT) pathology, dysfunction virtually all cell types brain, ultimately, overt neurodegeneration. Yet, large gaps our knowledge pathophysiology huge unmet medical need remain. Though largely conceptualize as aging, heritable non-heritable factors impact brain physiology, either continuously or specific points during lifespan, thereby alter risk for devolvement AD. Herein, I describe lifelong journey healthy from birth death with AD, while acknowledging many remain regarding understanding pathogenesis. To ensure current lexicon surrounding changes inevitable, incurable, poorly manageable preventable, curable, must address these gaps, develop therapies bigger on clinical symptoms progression use interventions appropriate stage disease.

Language: Английский

---

Detection of β-amyloid positivity in Alzheimer’s Disease Neuroimaging Initiative participants with demographics, cognition, MRI and plasma biomarkers

Brain Communications, Journal Year: 2021, Volume and Issue: 3(2)

Published: Feb. 2, 2021

gold standard for the ante-mortem assessment of brain β-amyloid pathology is currently positron emission tomography or cerebrospinal fluid measures

Language: Английский

---

Development of Alzheimer’s Disease Biomarkers: From CSF- to Blood-Based Biomarkers

Biomedicines, Journal Year: 2022, Volume and Issue: 10(4), P. 850 - 850

Published: April 5, 2022

In the 115 years since discovery of Alzheimer’s disease (AD), our knowledge, diagnosis, and therapeutics have significantly improved. Biomarkers are primary tools for clinical research, diagnostics, therapeutic monitoring in trials. They provide much insightful information, while they not clinically used routinely, help us to understand mechanisms this disease. This review charts journey AD biomarker development from cerebrospinal fluid (CSF) amyloid-beta 1-42 (Aβ42), total tau (T-tau), phosphorylated (p-tau) biomarkers imaging technologies next generation biomarkers. We also discuss advanced high-sensitivity assay platforms CSF Aβ42, T-tau, p-tau, blood analysis. The recently proposed Aβ deposition/tau biomarker/neurodegeneration or neuronal injury (ATN) scheme might facilitate definition biological status underpinning offer a common language among researchers across biochemical imaging. Moreover, we highlight blood-based that scalable alternative through cost-saving reduced invasiveness, may an understanding initiation development. different groups candidates, their advantages limitations, paths forward, identification analysis validation. valid implementation future diagnostics.

Language: Английский

---

Longitudinal changes in Alzheimer's‐related plasma biomarkers and brain amyloid

Alzheimer s & Dementia, Journal Year: 2023, Volume and Issue: 19(10), P. 4335 - 4345

Published: May 22, 2023

Understanding longitudinal plasma biomarker trajectories relative to brain amyloid changes can help devise Alzheimer's progression assessment strategies.

Language: Английский

---